Neurology
X-Linked Adrenoleukodystrophy
7
Pipeline Programs↗
0
Active Trials↗
4
Companies Involved↗
X-linked adrenoleukodystrophy is an early-stage landscape with 7 programs across 4 companies. The most active players are Minoryx Therapeutics, S.L., Takeda, Boehringer Ingelheim. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 3
No programs
Analysis
Trial Status
5
clinical trials
Withdrawn3 · 60%
Completed1 · 20%
Unknown status1 · 20%
Clinical Trials
Trial Activity
Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)
Withdrawn·—·Phase 1·NCT01787578
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
Completed·—·N/A·NCT01165060·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)